Literature DB >> 30676820

Acute cannabis toxicity.

Matthew J Noble1, Katrina Hedberg2, Robert G Hendrickson1.   

Abstract

Objective: We describe the clinical effects of, and products associated with, acute exposures to cannabis during the early legalization period of recreational cannabis in Oregon and Alaska.
Methods: This was an observational study of Oregon/Alaska Poison Center data between 4 December 2015 and 15 April 2017. A standardized data collection instrument was created for this study that captured information about cannabis product description, route of exposure, intentional vs unintentional exposure, product dose, product manufacture source, product ownership source, initial vital signs, clinical signs and symptoms, and subject disposition. Subjects were included if the Poison Center received a call about an acute exposure to cannabis from the subject, subject's family member or friend, or healthcare worker participating in the subject's care. Subjects were excluded if there was no evident exposure, the exposure was chronic, there were co-ingestants, or the subject was non-human (e.g. pet).
Results: Two hundred fifty three individuals were acutely exposed to cannabis (median age 20 years; range 8 months - 96 years; 54.2% males): 71 (28.1%) children (<12 years), 42 (16.6%) adolescents (12-17 years), and 140 (55.3%) adults (≥18 years). Children were most likely to unintentionally (98.6%) ingest (97.2%) homemade (35.2%) edibles (64.8%) belonging to a family member (73.2%) and experience sedation (52.1%). Adults were most likely to intentionally (88.6%) ingest (66.4%) retail (40.0%) edibles (48.6%) and experience neuroexcitation (47.1%). Adolescents' exposures had similarities to both adult and children; they were most likely to intentionally (81.0%) ingest (50.0%) homemade (23.8%) edibles (45.2%) belonging to a friend (47.3%) and to experience either neuroexcitation (42.9%) or sedation (40.5%). Among all ages, tachycardia and neuroexcitation were more likely following inhalation exposures compared to ingestions. Eight subjects were admitted to an intensive care unit, including three patients who were intubated; one subject died. Edibles were the most common products to cause symptoms in all age groups, while concentrated products were more likely to lead to intubation, especially when ingested. Children in particular had a higher likelihood of intensive care unit admission and intubation following exposure to concentrated products. Conclusions: Neurotoxicity is common after acute cannabis exposures. Children experienced unintentional exposures, particularly within the home and occasionally with major adverse outcomes. Concentrated products such as resins and liquid concentrates were associated with greater toxicity than other cannabis products. These findings may help guide other states during the early retail cannabis legalization period.

Entities:  

Keywords:  Marijuana; cannabis; overdose; poisoning; toxicity

Mesh:

Year:  2019        PMID: 30676820     DOI: 10.1080/15563650.2018.1548708

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  8 in total

1.  Copycat and lookalike edible cannabis product packaging in the United States.

Authors:  Danielle C Ompad; Kyle M Snyder; Simon Sandh; Daniel Hagen; Kewanda J Collier; Emily Goldmann; Melody S Goodman; Andy S L Tan
Journal:  Drug Alcohol Depend       Date:  2022-03-15       Impact factor: 4.852

2.  Accidental Ingestion of Tetrahydrocannabinol-Laced Gummies Causing Bradycardia and First-Degree Atrioventricular Block in a Pediatric Patient: A Case Report.

Authors:  Isra Idris; John R Diez; Betty Ansong Assoku; Susan Beker
Journal:  Cureus       Date:  2022-07-13

Review 3.  Medical Cannabis for the Primary Care Physician.

Authors:  Deepika Slawek; Senthil Raj Meenrajan; Marika Rose Alois; Paige Comstock Barker; Irene Mison Estores; Robert Cook
Journal:  J Prim Care Community Health       Date:  2019 Jan-Dec

4.  American Epilepsy Society (AES): Written Comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019.

Authors:  Timothy E Welty; Kevin E Chapman; R Edward Faught; Robert J Kotloski
Journal:  Epilepsy Curr       Date:  2019-10-22       Impact factor: 7.500

Review 5.  The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review.

Authors:  Kevin M Takakuwa; Raquel M Schears
Journal:  Int J Emerg Med       Date:  2021-02-10

6.  Penile self-amputation due to cannabis-induced psychosis: a case report.

Authors:  Nantanan Jengsuebsant; Sirapat Benjachaya; Jaraspong Vuthiwong; Theerapon Tangsuwanaruk
Journal:  J Med Case Rep       Date:  2022-01-30

Review 7.  Addressing adolescent substance use with a public health prevention framework: the case for harm reduction.

Authors:  James Michael Winer; Amy M Yule; Scott E Hadland; Sarah M Bagley
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

8.  Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.

Authors:  Guy Hindley; Katherine Beck; Faith Borgan; Cedric E Ginestet; Robert McCutcheon; Daniel Kleinloog; Suhas Ganesh; Rajiv Radhakrishnan; Deepak Cyril D'Souza; Oliver D Howes
Journal:  Lancet Psychiatry       Date:  2020-03-17       Impact factor: 77.056

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.